Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03099174
Recruitment Status : Recruiting
First Posted : April 4, 2017
Last Update Posted : March 6, 2019
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : April 10, 2020
  Estimated Study Completion Date : November 8, 2021